Xtl Biopharmaceuticals annual depreciation and amortization
2015
2016
2017
2020
2021
2022
2023
2024
2025
Xtl Biopharmaceuticals Depreciation & Amortization Growth & History (XTLB)
Xtl Biopharmaceuticals's depreciation and amortization was $0 for fiscal 2025.
View full Xtl Biopharmaceuticals company overviewXtl Biopharmaceuticals annual depreciation and amortization history
| Fiscal year | Period ended | Depreciation and amortization | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | $0 | −$364,000 | — |
| 2024 | 2024-12-31 | $364,000 | $364,000 | — |
| 2023 | 2023-12-31 | $0 | −$1,000 | — |
| 2022 | 2022-12-31 | $1,000 | $0 | 0.00% |
| 2021 | 2021-12-31 | $1,000 | $0 | 0.00% |
| 2020 | 2020-12-31 | $1,000 | — | — |
| 2017 | 2017-12-31 | $1,000 | −$2,000 | −66.67% |
| 2016 | 2016-12-31 | $3,000 | −$4,000 | −57.14% |
| 2015 | 2015-12-31 | $7,000 | — | — |
Xtl Biopharmaceuticals depreciation and amortization trends
Over the last five fiscal years, Xtl Biopharmaceuticals's depreciation and amortization decreased from $1,000 to $0, a change of −$1,000.
About the metric
What depreciation and amortization mean
Depreciation and amortization allocate the cost of tangible and intangible assets over their useful lives. These non-cash expenses reduce reported earnings and are commonly added back when calculating EBITDA and operating cash flow.
Calculation and source
Reported depreciation and amortization
TickerStat uses a combined depreciation and amortization value when reported. If a company reports the two components separately for an aligned period, they are added together without duplicating overlapping facts. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Xtl Biopharmaceuticals source filings ↗